Rozerem Molecule
Ramelteon, C16H21NO2 , and molecular mass of 259.343 g/mol is marketed as Rozerem by Takeda Pharmaceuticals North America, is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN), versus binding to GABA A receptors, such as with drugs like zolpidem, eszopiclone, and zaleplon. Ramelteon is approved by the FDA for long-term use. For complete text click here.
|
|
To
Rotate Molecule
-->> To
Zoom-->> Jmol
Menu --->> To view in Chime -- PDB Structure of the Rozerem molecule
|
|